STAT

Opinion: For African women at risk of HIV, a woke world is still sound asleep

As a daughter who lost both of her parents to HIV/AIDS, as well as the mother of a young African woman, I believe that investing in African-led and women-led HIV…
A woman prepares her pill box with antiretrovirals at an HIV/AIDS clinic in Cape Town, South Africa.

The arrival in 2012 of a daily pill to prevent HIV infection was widely hailed as a breakthrough that could drive new infections worldwide to very low levels. Eight years later, it is having a strong impact in some places and little or none in others.

The real-world impact of pre-exposure prophylaxis, PrEP for short, certainly isn’t living up to its high expectations among young women in sub-Saharan Africa, who account for more than one-quarter of the 800,000 new that occurred last year in the region.

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Biocon Eyeing Weight Loss Drugs, Sanofi Layoffs, And More
Biocon is pivoting to weight loss drugs as patents for the blockbuster medicines start to expire, unleashing a coming wave of generics.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly’s Zepbound For Sleep Apnea, The FDA Budget, And More
Eli Lilly reported positive results for Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An OptumRx Contract, 340B Dispute Resolution, And More
Cardinal Health announced its pharmaceutical distribution contracts with UnitedHealth's OptumRx unit will not be renewed after they expire in June.

Related Books & Audiobooks